Home › Companies › AGIOS PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 20, 2024: 6 items on AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2024: 2 approved · 4 passed (calculated).
Notable dissent: 2 directors (10.8%, 10.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AGIOS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AGIOS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kaye Foster | 45,821,431 | -- | -- | 5,297,937 | 1,255,248 | 90% | Passed (calculated) | — |
| Elect Director: Maykin Ho, Ph.D. | 46,670,795 | -- | -- | 4,448,573 | 1,255,248 | 91% | Passed (calculated) | — |
| Elect Director: Jeffrey Capello | 47,839,112 | -- | -- | 3,280,256 | 1,255,248 | 94% | Passed (calculated) | — |
| Elect Director: Catherine Owen | 45,595,875 | -- | -- | 5,523,493 | 1,255,248 | 89% | Passed (calculated) | — |
| 2. Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. | 47,985,871 | 3,120,093 | 13,404 | -- | 1,255,248 | 94% | Approved | — |
| 3. Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year. | 52,301,377 | 70,843 | 2,396 | -- | 0 | 99.9% | Approved | — |
Source: AGIOS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
205 asset managers disclosed a vote on at least one AGIOS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Catherine Owen
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Catherine Owen”): 45,595,875 for, 5,523,493 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,334,660 | 0 | 0 | 0 | For |
| Dimensional | 2,254,003 | 0 | 0 | 0 | For |
| T. Rowe Price | 622,367 | 0 | 0 | 1,536,244 | Mixed |
| BlackRock | 2,043,012 | 0 | 0 | 0 | For |
| State Street | 1,715,919 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,611,058 | 0 | 0 | 0 | For |
| Fidelity | 158,362 | 0 | 0 | 1,203,107 | Mixed |
| JPMorgan | 1,187,008 | 0 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 195,717 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 187,373 | 0 | 0 | 0 | For |
| Equitable | 85,297 | 0 | 0 | 75,978 | Mixed |
| TIAA | 154,678 | 0 | 0 | 0 | For |
| Prudential/PGIM | 78,260 | 0 | 0 | 64,828 | Mixed |
| First Trust | 131,432 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 115,183 | 0 | 0 | 0 | For |
| Brighthouse | 62,102 | 0 | 0 | 46,240 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 103,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 96,035 | 0 | 0 | 0 | For |
| AMG FUNDS | 0 | 0 | 0 | 93,104 | Withhold |
| American Century | 82,007 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 69,358 | 0 | 0 | 0 | For |
| John Hancock | 26,502 | 0 | 0 | 33,034 | Mixed |
| Lincoln Financial | 54,469 | 0 | 0 | 0 | For |
| ProShares | 46,735 | 0 | 0 | 0 | For |
Fund voting reports, all 69 managers: 18,259,940 for, 3,150,360 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,254,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,254,900 for.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jeffrey Capello
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jeffrey Capello”): 47,839,112 for, 3,280,256 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,334,660 | 0 | 0 | 0 | For |
| Dimensional | 2,254,003 | 0 | 0 | 0 | For |
| T. Rowe Price | 622,367 | 0 | 0 | 1,536,244 | Mixed |
| BlackRock | 2,043,012 | 0 | 0 | 0 | For |
| State Street | 1,715,919 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,611,058 | 0 | 0 | 0 | For |
| Fidelity | 1,361,469 | 0 | 0 | 0 | For |
| JPMorgan | 1,187,008 | 0 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 195,717 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 187,373 | 0 | 0 | 0 | For |
| Equitable | 149,737 | 0 | 0 | 11,538 | Mixed |
| TIAA | 154,678 | 0 | 0 | 0 | For |
| Prudential/PGIM | 114,560 | 0 | 0 | 28,528 | Mixed |
| First Trust | 131,432 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 115,183 | 0 | 0 | 0 | For |
| Brighthouse | 62,102 | 0 | 0 | 46,240 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 103,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 96,035 | 0 | 0 | 0 | For |
| AMG FUNDS | 93,104 | 0 | 0 | 0 | For |
| American Century | 82,007 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 69,358 | 0 | 0 | 0 | For |
| John Hancock | 26,502 | 0 | 0 | 33,034 | Mixed |
| Lincoln Financial | 54,469 | 0 | 0 | 0 | For |
| ProShares | 46,735 | 0 | 0 | 0 | For |
Fund voting reports, all 69 managers: 19,726,761 for, 1,683,539 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,254,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,254,900 for.
Combines 5 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Kaye Foster
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kaye Foster”): 45,821,431 for, 5,297,937 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,334,660 | 0 | 0 | 0 | For |
| Dimensional | 2,254,003 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 2,158,611 | Withhold |
| BlackRock | 2,043,012 | 0 | 0 | 0 | For |
| State Street | 1,715,919 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,611,058 | 0 | 0 | 0 | For |
| Fidelity | 1,361,469 | 0 | 0 | 0 | For |
| JPMorgan | 1,187,008 | 0 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 195,717 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 187,373 | 0 | 0 | 0 | For |
| Equitable | 85,297 | 0 | 0 | 75,978 | Mixed |
| TIAA | 154,678 | 0 | 0 | 0 | For |
| Prudential/PGIM | 114,560 | 0 | 0 | 28,528 | Mixed |
| First Trust | 131,432 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 115,183 | 0 | 0 | 0 | For |
| Brighthouse | 62,102 | 0 | 0 | 46,240 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 103,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 96,035 | 0 | 0 | 0 | For |
| AMG FUNDS | 93,104 | 0 | 0 | 0 | For |
| American Century | 82,007 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 69,358 | 0 | 0 | 0 | For |
| John Hancock | 26,502 | 0 | 0 | 33,034 | Mixed |
| Lincoln Financial | 54,469 | 0 | 0 | 0 | For |
| ProShares | 46,735 | 0 | 0 | 0 | For |
Fund voting reports, all 69 managers: 18,981,913 for, 2,416,431 withheld, 11,956 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,254,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,254,900 for.
Combines 6 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Maykin Ho, Ph.D.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Maykin Ho, Ph.D.”): 46,670,795 for, 4,448,573 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,334,660 | 0 | 0 | 0 | For |
| Dimensional | 2,254,003 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 2,158,611 | Withhold |
| BlackRock | 2,043,012 | 0 | 0 | 0 | For |
| State Street | 1,715,919 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,611,058 | 0 | 0 | 0 | For |
| Fidelity | 1,361,469 | 0 | 0 | 0 | For |
| JPMorgan | 1,187,008 | 0 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 195,717 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 187,373 | 0 | 0 | 0 | For |
| Equitable | 85,297 | 0 | 0 | 75,978 | Mixed |
| TIAA | 154,678 | 0 | 0 | 0 | For |
| Prudential/PGIM | 114,560 | 0 | 0 | 28,528 | Mixed |
| First Trust | 131,432 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 115,183 | 0 | 0 | 0 | For |
| Brighthouse | 62,102 | 0 | 0 | 46,240 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 103,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 96,035 | 0 | 0 | 0 | For |
| AMG FUNDS | 93,104 | 0 | 0 | 0 | For |
| American Century | 82,007 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 69,358 | 0 | 0 | 0 | For |
| John Hancock | 26,502 | 0 | 0 | 33,034 | Mixed |
| Lincoln Financial | 54,469 | 0 | 0 | 0 | For |
| ProShares | 46,735 | 0 | 0 | 0 | For |
Fund voting reports, all 69 managers: 19,039,954 for, 2,370,346 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,254,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,254,900 for.
Combines 7 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 90.9% for (June 13, 2023 meeting) ▲ 3.0 pts
Description as filed by funds: TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 47,985,871 for, 3,120,093 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,334,660 | 0 | 0 | 0 | For |
| Dimensional | 2,254,003 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,158,611 | 0 | 0 | 0 | For |
| BlackRock | 2,043,012 | 0 | 0 | 0 | For |
| State Street | 1,715,919 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,611,058 | 0 | 0 | 0 | For |
| Fidelity | 1,361,469 | 0 | 0 | 0 | For |
| JPMorgan | 1,187,008 | 0 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 195,717 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 187,373 | 0 | 0 | 0 | For |
| Equitable | 161,275 | 0 | 0 | 0 | For |
| TIAA | 154,678 | 0 | 0 | 0 | For |
| Prudential/PGIM | 143,088 | 0 | 0 | 0 | For |
| First Trust | 131,432 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 115,183 | 0 | 0 | 0 | For |
| Brighthouse | 108,342 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 103,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 96,035 | 0 | 0 | 0 | For |
| AMG FUNDS | 93,104 | 0 | 0 | 0 | For |
| American Century | 82,007 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 69,358 | 0 | 0 | Against |
| John Hancock | 59,536 | 0 | 0 | 0 | For |
| Lincoln Financial | 54,469 | 0 | 0 | 0 | For |
| ProShares | 46,735 | 0 | 0 | 0 | For |
Fund voting reports, all 69 managers: 21,320,297 for, 90,003 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 4,220,024 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,909,534 | 0 | 0 | 0 | For |
| State Street | 2,812,430 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 2,254,900 | 0 | 0 | 0 | For |
| JPMorgan | 2,113,701 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,844,938 | 0 | 0 | 0 | For |
| BlackRock | 1,843,037 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,765,115 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 1,370,496 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,294,687 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,284,370 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,108,613 | 0 | 0 | Against |
| Vestal Point Capital, LP | 625,000 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 560,499 | 3,400 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 488,949 | 0 | 0 | 0 | For |
| Northern Trust | 454,633 | 35 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| Eagle Health Investments LP | 330,830 | 0 | 0 | 0 | For |
| Citadel | 311,041 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 288,974 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 275,242 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 265,586 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 264,559 | 0 | 0 | Against |
| Caligan Partners LP | 216,656 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 205,095 | 0 | 0 | 0 | For |
Institutional-manager reports, all 155 managers: 30,802,651 for, 1,984,574 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 96.4% for (June 13, 2023 meeting) ▲ 3.5 pts
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 52,301,377 for, 70,843 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,334,660 | 0 | 0 | 0 | For |
| Dimensional | 2,254,003 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,158,611 | 0 | 0 | 0 | For |
| BlackRock | 2,043,012 | 0 | 0 | 0 | For |
| State Street | 1,715,919 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,611,058 | 0 | 0 | 0 | For |
| Fidelity | 1,361,469 | 0 | 0 | 0 | For |
| JPMorgan | 1,187,008 | 0 | 0 | 0 | For |
| Charles Schwab | 443,808 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 195,717 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 187,373 | 0 | 0 | 0 | For |
| Equitable | 161,275 | 0 | 0 | 0 | For |
| TIAA | 154,678 | 0 | 0 | 0 | For |
| Prudential/PGIM | 143,088 | 0 | 0 | 0 | For |
| First Trust | 131,432 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 115,183 | 0 | 0 | 0 | For |
| Brighthouse | 108,342 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 103,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 96,035 | 0 | 0 | 0 | For |
| AMG FUNDS | 93,104 | 0 | 0 | 0 | For |
| American Century | 82,007 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 69,358 | 0 | 0 | 0 | For |
| John Hancock | 59,536 | 0 | 0 | 0 | For |
| Lincoln Financial | 54,469 | 0 | 0 | 0 | For |
| ProShares | 46,735 | 0 | 0 | 0 | For |
Fund voting reports, all 69 managers: 21,387,942 for, 22,358 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,254,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,254,900 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 56,751,511 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.16% |
| 2 | Dimensional | 3.97% |
| 3 | T. Rowe Price | 3.80% |
| 4 | BlackRock | 3.60% |
| 5 | State Street | 3.02% |
| 6 | Delaware/Macquarie | 2.84% |
| 7 | Fidelity | 2.40% |
| 8 | JPMorgan | 2.09% |
| 9 | Charles Schwab | 0.78% |
| 10 | AIG/SunAmerica | 0.34% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 7.44% |
| 2 | T. Rowe Price | 5.13% |
| 3 | State Street | 4.96% |
| 4 | Erste Asset Management GmbH | 3.97% |
| 5 | JPMorgan | 3.72% |
| 6 | ARMISTICE CAPITAL, LLC | 3.25% |
| 7 | BlackRock | 3.25% |
| 8 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 3.11% |
| 9 | ArrowMark Colorado Holdings LLC | 2.41% |
| 10 | Rock Springs Capital Management LP | 2.28% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 5,604,876 | 9.88% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 4,545,738 | 8.01% | Form 13F, quarter ended March 31, 2024 |
| BB Biotech AG | 4,000,000 | 7.05% | Schedule 13G, filed February 13, 2024 |
| State Street | 3,138,197 | 5.53% | Form 13F, quarter ended March 31, 2024 |
| Dimensional Fund Advisors | 2,578,558 | 4.54% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 2,012,993 | 3.55% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,282,915 | 2.26% | Form 13F, quarter ended March 31, 2024 |
| Citadel Advisors | 1,042,961 | 1.84% | Form 13F, quarter ended March 31, 2024 |
| Goldman Sachs | 804,766 | 1.42% | Form 13F, quarter ended March 31, 2024 |
| Northern Trust | 590,493 | 1.04% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 56,751,511 shares outstanding, as reported by AGIOS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AGIOS PHARMACEUTICALS INC.'s shareholder meeting held June 20, 2024, in the 2023-2024 proxy season, 205 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,573 separate fund positions. On the most widely held item on that ballot — TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — AGIOS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AGIOS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AGIOS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AGIOS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “AGIOS PHARMACEUTICALS (AGIO) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/agios-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.